AMGEN TO PRESENT NEW REPATHA® (EVOLOCUMAB) AND OLPASIRAN DATA AT ACC| Amgen
Amgen (AMGN) presented new data on Repatha (evolocumab) and olpasiran at ACC.23/WCC. Repatha reduced CV events in ASCVD patients when used earlier and longer. Olpasiran reduced Lp(a) by 90% regardless of baseline levels. Amgen also hosted an LDL-C Action Summit to improve CVD care in the U.S.
How this was made
The 30-second read
Why it matters
The disclosed data provide fresh evidence of clinical benefit, which may influence analyst forecasts and investor sentiment toward Amgen and the broader cardiovascular drug space.
Market read
First public disclosure of combined trial data could lift Amgen's valuation and impact the lipid‑therapy sector.
What to watch
Repatha's pricing pressure and competition from newer lipid agents could limit upside despite positive trial outcomes.
Background
Amgen's press release highlights combined Phase 3 FOURIER results and Phase 2 olpasiran data, positioning the company as a leader in LDL‑C and Lp(a) reduction ahead of a major cardiology conference.
Ticker impact
Amgen announced new combined FOURIER data showing Repatha reduces cardiovascular events and Phase 2 olpasiran data cutting Lp(a) >90%, to be presented at the ACC meeting.
likely upward pressure as market absorbs favorable trial results
First disclosure of robust cardiovascular outcome data and a promising siRNA candidate typically drives optimism for biotech stocks.
Market effects
Strengthens the lipid‑lowering and cardiovascular therapeutics sector, potentially benefiting peers with PCSK9 or Lp(a) programs.
U.S. biotech market may see modest gains as investors reassess cardiovascular pipeline valuations.
Global investors tracking cholesterol‑lowering therapies could adjust exposure to Amgen and similar biotech firms.
Counterpoint
If the data do not translate into regulatory approval or commercial uptake, the hype could fade and the stock may underperform.
Key entities
- CompanyAmgen
Biotech firm presenting new cardiovascular outcome data for Repatha and olpasiran.
- DrugRepatha (evolocumab)
PCSK9 inhibitor showing reduced CV events in combined FOURIER analysis.
- DrugOlpasiran
Investigational siRNA reducing Lp(a) by >90% in Phase 2 study.
